'Broad Daylight Dacoity': Supreme Court Slams ₹27,000 MRP On Essential Cancer Medicines, Questions Authorities Over Lack Of Action
New Delhi: Terming it a "broad daylight dacoity" against patients, the Supreme Court on Tuesday expressed shock over the overpricing of essential cancer medicines, noting that one drug carried an MRP of Rs 27,000 despite being supplied to retailers for Rs 2,700. Also Watch: "It is very surprising that the authorities who are supposed to take action on this are silent," a bench of Justices Vikram…
The Supreme Court has expressed shock over the outrageous pricing of essential cancer medicines, branding it as "broad daylight dacoity" against patients. A bench of Justices Vikram Nath and Sandeep Mehta noted that one drug had an MRP (Maximum Retail Price) of Rs 27,000, despite being supplied to retailers for merely Rs 2,700. This price discrepancy is ten times higher than the rate at which the medicine is provided to retailers.
The court questioned the authorities for their apparent silence on the matter, emphasizing the severe impact on patients who often have to sell their possessions to afford treatment. The court emphasized the critical importance of fixing the MRP of medicines and expressed surprise at the lack of action from the authorities. The bench posted the matter for further hearing on September 29, seeking directions to ensure strict price control under the Drugs (Prices Control) Order, 2013 to prevent unethical overpricing and disproportionate profit-making by pharma companies and retailers.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
